Background-Pyridostigmine, an acetylcholinesterase antagonist, is useful in improving respiratory function in patients with myasthenia gravis. More recently, plasma exchange has been employed in myasthenia gravis because it acts presumably by removal of circulating antibodies against acetylcholine receptors. Surprisingly, comparative data on the effects of pyridostigmine and plasma exchange on lung volumes, respiratory muscle strength, and ventilatory control system in patients with myasthenia gravis are lacking. Methods -Nine consecutive patients with grade Ilb myasthenia gravis were studied under control conditions and after a therapeutic dose of pyridostigmine. In a second study the patients were re-evaluated a few days after a cycle of plasma exchange, before taking pyridostigmine. In each subject pulmonary volumes, inspiratory (MIP) and expiratory (MEP) muscle force, and respiratory muscle strength, calculated as average MIP and MEP as percentages of their predicted values, were measured. The ventilatory control system was evaluated in terms of volume (tidal volume, VT) and time (inspiratory time, TI, and total time, TTOT) components of the respiratory cycle. Mean inspiratory flow (VT/TI) -that is, the "driving" -and TI/TToT -that is, the "timing" -components ofventilation were also measured.
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Results -In each patient treatment relieved weakness and tiredness, and dyspnoea grade was reduced with plasma exchange. Following treatment, vital capacity (VC) increased on average by 9-7% with pyridostigmiine and by 14% with plasma exchange, and MIP increased by 18% and 26%, respectively. In addition, with plasma exchange but not with pyridostigmine forced expiratory volume in one second (FEV1) increased by 16% and MEP increased by 24-5%, while functional residual capacity (FRC) decreased a little (6-8%) . The change in respiratory muscle strength was related to change in VC (r2 = 0.48). With plasma exchange, VT increased by 18*6% and VT/TI increased by 13-5%, while neither TI nor TIrrTOT changed.
Conclusions -Plasma exchange can be used in patients with myasthenia gravis when symptoms are not adequately controlled by anticholinesterase agents. Plasma exchange increases respiratory muscle force and tidal volume due to changes in "driving" but not "timing" of the respiratory cycle.
Plasma exchange is regarded as an established method for treating patients with myasthenia gravis when other treatments have been ineffective.1`It can also be used to reduce surgical complications of thymectomy. Under these circumstances plasma exchange is thought to act by reducing circulating antibodies against the acetylcholine receptor (AChR),l the plasma factor directly concerned in producing the disorders of neuromuscular transmission in the acquired form of the disease. 45 Several studies have reported the effects of pyridostigmine, a cholinesterase inhibitor, on respiratory muscle function in patients with myasthenia gravis. 8 Black and Hyatt. '9 After baseline routine testing while breathing room air the ventilatory pattern was evaluated. The subjects, wearing a noseclip, were put in a comfortable supine position breathing through a mouthpiece on a circuit where the inspiratory and expiratory lines were separated by a one-way valve (Hans-Rudolph, Kansas City, Missouri, USA). Airflow was measured with a Fleisch type 3 pneumotachograph and the flow signal was integrated into the volume. From the spirogram the following breath-bybreath time and volume components of the respiratory cycle were derived: inspiratory time (TI), expiratory time (TE), total time of the respiratory cycle (TTOT), and tidal volume (VT). Mean inspiratory flow (VT/TI) "driving", duty cycle (Ti/TToT) "timing", respiratory frequency (Rf= 1/TTOT x 60), and instantaneous ventilation (VE =VT x RJ) were also calculated. Expired CO2 (Pco2) was sampled continuously at the mouth by an infrared CO2 meter. The values for dead space and resistance of the system up to a flow of 4 1/s were 178 ml and 0 92 cm H20/l/s, respectively. Details of the methods have been described previously.820
The output ofthe CO2 meter, the flow signal, and the integrated flow signal were recorded continuously on a multichannel chart recorder. After a 10 minute adaptation period the baseline evaluation was started.
Ventilatory parameters were calculated from the data averaged from the breaths recorded over 10 minutes.
PLASMAPHERESIS
Plasma exchange was performed using a discontinuous flux cellular separator (Dideco model Progress BT 790A) and by mono-use cell apheresis (Dideco model BT 225). Perfusion of plasma substitutes consisted of: (a) 750-1000 ml saline, (b) 500 ml 10% colloidal solution of low molecular weight dextran in saline, (c) As a group the patients exhibited a more rapid and shallow breathing pattern: smaller VT, n and greater Rf and VTM. All these differences were significant (p<0-025 to <0 005). In contrast, ventilation (VE) was similar in the patients and controls.
As shown in table 2 and fig 1, pyridostigmine and plasma exchange both resulted in a sig- In each patient treatment relieved weakness and tiredness. In particular, with plasma exchange the improvement began within a few days of initiating exchange and continued for some days after the cycle ceased; dyspnoea grade lessened from III to II in some patients and from II to I (hurrying on a level or walking up a slight hill) in the others. Autoantibody levels always changed after plasma exchange (table 1) .
In the third study the two hour increases in respiratory muscle strength (fig 3) 
tract and action at the neuromuscular junction. Furthermore, the criteria for assessing benefit from oral pyridostigmine in patients with myasthenia gravis often relies solely on a patient's subjective response with improvement in chewing, swallowing, or less ocular, facial or limb weakness. We have found that two hours after oral administration of 120 mg pyridostigmine the changes in lung volumes did not substantially differ from the changes after 30 minutes, whether recorded on the day when on or off corticosteroids. This finding agrees with the data of Shale et al. 26 In terms of respiratory muscle strength, after the initial increase of 22% and 35% from control in MIP and MEP, respectively, these parameters did not increase any further, consistent with the observations of Rindgqvist and Rindgqvist,24 in whose study the maximum increase in MIP and MEP after neostigmine injection was 17% and 15% predicted respectively. Similarly, in the study by Mier-Jedrzejowicz et al7 MIP increased by a mean of 37% and MEP by a mean of 28% after administration of intravenous edrophonium.
The low MIP and MEP values found in our patients are likely to reflect respiratory muscle weakness -that is, the failure to generate force. In patients with myasthenia gravis inspiratory muscle weakness might depend on the defect in neuromuscular transmission and corticosteroid myopathy which is a well known adverse effect from corticosteroid treatment.2728 There is considerable evidence that abnormalities at the neuromuscular junction are the major problem in myasthenia gravis. Because patients with myasthenia gravis vary in the time of their optimal strength with dose regimen, each patient should be studied on either their day on or off steroid. The results from our third study showed that changes in pulmonary volumes and respiratory muscle strength were indifferent to the corticosteroid regimen, and this argues against a possible undesirable influence on our results by the fact that our patients received alternate day corticosteroid therapy. In addition, our observation that the response to pyridostigmine did not differ between days on and off steroid supports this as a safe and satisfactory dose regimen for patients with myasthenia gravis.
Our patients had a rapid and shallow breathing pattern -that is, the respiratory central output was modulated via shorter inspiratory time (Tm) into a tachypnoeic pattern of breathing and smaller VT. This more rapid and shallow breathing is similar to that observed in patients with several neuromuscular disorders8-13435 including myasthenic myopathy29 with chronic934 or acute'01' ventilatory failure. In neuromuscular disorders either afferent information from weak respiratory muscles3637 and stiffened rib cage,34 or Gori, Spinelli, Marconi, Duranti, Gigliotti, Pizzi, Scano We conclude that plasma exchange can be used in patients with myasthenia gravis whose symptoms are not completely controlled by anticholinesterase agents, and that plasma exchange increases respiratory muscle force and tidal volume by a change in the "driving" but not the "timing" of the respiratory cycle. 
